Advanced Oncotherapy Regulatory News (AVO)

26 November2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Appointment of Bob Rose to establish Global Manufacturing and Supply Chain function

Advanced Oncotherapy (AIM: AVO) announces the appointment of Robert Rose to the executive team of the Company as Director of Global Manufacturing and Supply Chain Management. Bob Rose is a global operations and supply chain professional with over 30 years' experience of delivering business and supply chain transformation, programme direction, strategic business plans, procurement and lean manufacturing management. He has experience in high value, low to medium volume, specialised goods and services, capital equipment and advanced medical and scientific equipment.

Most recently, Bob has been working with oncology and neuroscience treatment equipment manufacturers Elekta Ltd to deliver an FDA and EU compliant supply chain based on multiple international manufacturers and suppliers in territories including China and Germany. The operation Bob managed passed a detailed external FDA audit, maintained ISO 13485 and 14971 and now supports over 450 complex capital equipment projects per annum with a value of over £500m.

As Director of global manufacturing and supply chain management, Bob will build a team to deliver the balance of plant required for the Company's next generation of proton therapy technology and will be responsible for the assembly of this with the patented linear accelerators supplied by Advanced Oncotherapy's ADAM subsidiary based at CERN near Geneva. He will develop the Company's relationships with downstream engineering supply chain companies in Holland, Israel, Poland, the Czech Republic and France and help finalise the advanced discussions with precision engineering companies in Northern Ireland and established proton component manufacturing entities in the UK and US.

Bob will be based with the executive team in London and will report to Sanjeev Pandya, Chief Operating Officer and Executive Director.

Advanced Oncotherapy's COO Sanjeev Pandya, "I am delighted to welcome Bob on to our team. Bob has in-depth experience in managing complex cross-border manufacturing processes, and has consistently demonstrated achieving tough and exacting goals throughout his career. This, together with his calm persona, will ensure that we are able to hit our deadlines and commitments, and enable us to deliver our machines on time to all of our customers around the world."

Bob Rose added: "I am delighted to join the executive team at AVO at this exciting time. The international team of experts are at the stage of finalising development work on LIGHT - Linac Image Guided Hadron Therapy - and bringing it through prototyping and then into full production. I will be leading the manufacturing and supply chain team, effectively the 'engine room'.

"All the world's leading medical equipment manufacturers are in the process of restructuring their manufacturing bases. I have the ideal opportunity to lead and install lean six sigma discipline and business culture within Advanced Oncotherapy from the start - enabling us to focus from the beginning on quality and cost control.

"With the rapidly growing interest in LIGHT and the increasing demand due to rising cancer rates, we have the opportunity to build technical /manufacturing centres at the very heart of our customer market place, with the flexibility to develop rapidly as our market interests grow.

"Having worked for other leading internationally focused organisations and multicultural teams, I am looking forward to working closely with our growing team and all our partners to commercialise the next generation of cancer treatment that delivers precision radiation therapy with protons."

For further information, please visit www.avoplc.com or contact:

About Advanced Oncotherapy plc ("AVO")

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK through Spire and other hospitals.

About Lean Six Sigma

Lean Six Sigma is a highly disciplined process that helps us focus on developing and delivering near-perfect products and services. It began in 1986 as a statistically based method to reduce variation and improve quality in electronic manufacturing processes in Motorola, Inc. Today it is an all-encompassing business performance methodology in the most successful organizations. The three basic elements include (1) optimise processes to for efficiency and effectiveness, (2) design and introduce processes to ensure cost effective quality delivery to meet customer expectations and (3) measure process performance against objective key indicators and customer requirements.

-ends-